Market capitalization | $3.49b |
Enterprise Value | $3.08b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 8.88 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-781.27m |
Free Cash Flow (TTM) Free Cash Flow | $-485.24m |
Cash position | $437.10m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
12 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
12 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.72 -3.72 |
62%
62%
|
|
EBITDA | -778 -778 |
73%
73%
|
EBIT (Operating Income) EBIT | -781 -781 |
73%
73%
|
Net Profit | -747 -747 |
73%
73%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
Head office | Virgin Islands, British |
CEO | Vladimir Coric |
Employees | 239 |
Founded | 2022 |
Website | www.biohaven.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.